Ustekinumab 45 mg
Sponsors
Janssen Research & Development, LLC, Janssen Biotech, Inc., Celltrion HealthCare France
Conditions
Arthritis, PsoriaticAxial SpondyloarthritisCrohn DiseasePlaque PsoriasisPrimary Biliary CirrhosisPsoriasis
Phase 2
Phase 3
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
CompletedNCT01009086
Start: 2009-12-31End: 2013-05-31Updated: 2015-03-03
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
CompletedNCT01077362
Start: 2010-03-31End: 2012-11-30Updated: 2014-02-27
A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
CompletedNCT01550744
Start: 2012-03-31End: 2015-07-31Updated: 2017-02-09
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
TerminatedNCT02437162
Start: 2015-09-03End: 2017-09-06Updated: 2025-04-29
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
TerminatedNCT02438787
Start: 2015-07-31End: 2017-08-31Updated: 2025-04-29
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
CompletedNCT02698475
Start: 2016-05-31End: 2020-10-31Updated: 2021-11-01